Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised phase II screening study to be used in an TPF-chemotherapy [docetaxel + cisplatin + fluorouracil] (short induction) before TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/hypopharynx. [Randomised phase II screeningstudy to be used in a TP/TPF-chemotherapy (shortinduction) before TP/TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/ hypopharynx.]

X
Trial Profile

Randomised phase II screening study to be used in an TPF-chemotherapy [docetaxel + cisplatin + fluorouracil] (short induction) before TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/hypopharynx. [Randomised phase II screeningstudy to be used in a TP/TPF-chemotherapy (shortinduction) before TP/TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/ hypopharynx.]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
  • Indications Laryngeal cancer
  • Focus Therapeutic Use
  • Acronyms DeLOS II
  • Most Recent Events

    • 01 Oct 2018 Results published in the Annals of Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 25 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top